Dawn Duval

Clinical Sciences

ACC150 VTH

(970) 297-4064

About Dawn

I grew up on a cattle ranch in NE Nevada and began my research career as a Biochemistry undergraduate at the University of Nevada, Reno in the Allie M. Lee Natural Products Lab. My graduate research with Dr. Ruth Billings, a toxicologist in the Pharmacology department at UNR and later Environmental Health Sciences at CSU, explored the ability of cytokines to induce nitric oxide synthase expression in hepatocytes and the potential role this induction plays in liver damage. I expanded my understanding of mechanisms of gene regulation by completing post-doctoral fellowships with Dr. Colin Clay in the Physiology Department (now Biomedical Sciences) at CSU and as a postdoctoral fellow and junior faculty member in the Endocrine Division at the Univ. of Colorado School of Medicine. Current projects utilize next generation sequencing methods to explore genetic and gene expression changes contributing to cancer development, metastatic progression, and drug sensitivity in models of canine cancer including osteosarcoma and bladder cancer.

Education

BS, University of Nevada, Reno Major: Biochemistry Minor:Chemistry, Biology, 1989PhD, University of Nevada, Reno Cell and Molecular Pharmacology and Physiology Program, 1994Postdoctoral, Colorado State University: Physiology 1995-1999, 1999Postdoctoral/Junior Faculty, Endocrine Division, University of Colorado Anschutz Medical Campus 1999-2000, 2000

Publications

Das S, Idate R, Cronise KE, Gustafson DL, Duval DL. Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing. Mol Cancer Ther. 2019;18(8):1460-71. Epub 2019/06/09. doi: 10.1158/1535-7163.mct-18-1346. PubMed PMID: 31175136; PMCID: PMC6679748Cronise KE, Hernandez BG, Gustafson DL, Duval DL.(2019) Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. Molecular Pharmacology. 96(1), 36-46. doi:10.1124/mol.119.115808, PMID: 31048548Mannheimer, JD, Duval, DL, Prasad, A, and Gustafson, DL (2019). A systematic analysis of genomics-based modeling approaches for prediction of drug response to cytotoxic chemotherapies. BMC Medical Genomics (2019 Jun 17;12(1):87. doi: 10.1186/s12920-019-0519-2). PMID: 31208429Fowles JS, Dailey DD, Gustafson DL, Thamm DH and Duval DL (2017) The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine. Vet Comp Oncol.:15(2):481-492. doi: 10.1111/vco.12192. PMID: 27197945. Fowles, JS, Brown, KC, Hess, AM, Duval, DL, and Gustafson, DL (2016) Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma. BMC Bioinformatics 17:93. PMID: 26892349 Halsey, CH, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, and Thamm DH. (2014). Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia (R)) in canine mast cell tumor. BMC Veterinary Research 10:105. PMC4049511Kalet BT, Anglin SR, Handschy A, O’Donoghue LE, Halsey C, Chubb L, Korch C, and Duval DL, Transcription factor Ets1 cooperates with estrogen receptor a to stimulate estradiol-dependent growth in breast cancer cells and tumors, In review at PLOS one, November, 2012.Dailey DD, Anfinsen KP, O’Donoghue LE, Ehrhart EJ, Charles JB, Thamm DH, Powers BE, Jonasdottir TJ, and Duval DL .“HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors, Accepted with revisions at BMC Veterinary Research, Dec. 2012.Andrea Y. Angstadt, Alison Motsinger-Reif, Rachael Thomas, William C. Kisseberthe, C. Guillermo Coutoe, Dawn L. Duval, Dahlia M. Nielsen, Jaime F. Modiano, and Matthew Breen. Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: Signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart. Genes, Chromosomes & Cancer 2011, 50:859–874. Liza E. O’Donoghue, Andrey A. Ptitsyn, Debra A. Kamstock, Janet Siebert, Russell S. Thomas, and Dawn L. Duval. Expression profiling in canine osteosarcoma: identification of biomarkers and pathways associated with outcome. BMC Cancer. 2010 Sep 22;10(1):506.Sottnik JL, Duval DL, Ehrhart EJ, Thamm DH. An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. Clin Exp Metastasis. 2010 Mar;27(3):151-60. Epub 2010 Mar 7.L.E. O’Donoghue, Jason Rivest, and D.L. Duval, PCR-based Species Verification and Microsatellite Analysis for Canine Cell Line Validation. Submitted to J Vet. Diag. Invest. November 2010.A. Jean, A. Gutierrrez-Hartmann, and D.L. Duval. A Pit-1 Threonine 220 Phosphomimic Reduces Binding to Monomeric DNA Sites to Inhibit Ras and Estrogen Stimulation of the Prolactin Gene Promoter. Mol Endocrinol. 2010 Jan;24(1):91-103. Epub 2009 Nov 3.

Research Specialty

Classes Taught/Currently teaching:Classes Taught/Currently Teaching:Classes Taught/Currently Teaching: